Abstract
So far monotargeted therapies in Alzheimers disease (AD) led to insufficient results. Slight improvements in the AD symptomatics have been limited to patients in the early stage of the disease. So multitargeting approaches have been started addressing amyloid plaques as preferred primary target structures beside acetylcholine esterase inhibition. Various protein kinases have been discussed to make a contribution to the progression of AD. So protein kinases are promising target structures for a perspective multitargeting. We identified substituted smallmolecule protein kinase inhibitors of the tricyclic benzofuropyridine type which showed partly nanomolar affinities to AD-relevant glycogen synthase kinase (gsk) 3β, extracellular-signal regulated kinase (ERK) 2 and C-Jun-N-terminal kinase (JNK) 3. Substituent-dependent effects on the respective kinase inhibitions are discussed and inhibitor binding modes to those kinases are presented based on enzyme docking studies. Inhibitor effects on the tau protein target structure are shown for first compounds in cellular studies to prove the enzyme conditioned effects.
Keywords: Multitargeted approach, substituent effects, kinase inhibition, tau protein, enzyme binding, total tau.
Current Alzheimer Research
Title:Drug Development of Small-Molecule Inhibitors of AD-Relevant Kinases as Novel Perspective Multitargeted Approach
Volume: 13 Issue: 12
Author(s): V. Tell, I. Hilbrich, M. Holzer, Frank Totzke, Christoph Schachtele, Inna Slynko, Wolfgang Sippl and A. Hilgeroth
Affiliation:
Keywords: Multitargeted approach, substituent effects, kinase inhibition, tau protein, enzyme binding, total tau.
Abstract: So far monotargeted therapies in Alzheimers disease (AD) led to insufficient results. Slight improvements in the AD symptomatics have been limited to patients in the early stage of the disease. So multitargeting approaches have been started addressing amyloid plaques as preferred primary target structures beside acetylcholine esterase inhibition. Various protein kinases have been discussed to make a contribution to the progression of AD. So protein kinases are promising target structures for a perspective multitargeting. We identified substituted smallmolecule protein kinase inhibitors of the tricyclic benzofuropyridine type which showed partly nanomolar affinities to AD-relevant glycogen synthase kinase (gsk) 3β, extracellular-signal regulated kinase (ERK) 2 and C-Jun-N-terminal kinase (JNK) 3. Substituent-dependent effects on the respective kinase inhibitions are discussed and inhibitor binding modes to those kinases are presented based on enzyme docking studies. Inhibitor effects on the tau protein target structure are shown for first compounds in cellular studies to prove the enzyme conditioned effects.
Export Options
About this article
Cite this article as:
Tell V., Hilbrich I., Holzer M., Totzke Frank, Schachtele Christoph, Slynko Inna, Sippl Wolfgang and Hilgeroth A., Drug Development of Small-Molecule Inhibitors of AD-Relevant Kinases as Novel Perspective Multitargeted Approach, Current Alzheimer Research 2016; 13 (12) . https://dx.doi.org/10.2174/1567205013666160615091821
DOI https://dx.doi.org/10.2174/1567205013666160615091821 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Path from Anti Parkinson Drug Selegiline and Rasagiline to Multifunctional Neuroprotective Anti Alzheimer Drugs Ladostigil and M30
Current Alzheimer Research Dyslipidemia, Metabolic Syndrome and Vascular Disease Among Asian Indians
Vascular Disease Prevention (Discontinued) Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration
Current Vascular Pharmacology Hyperphosphorylation of Microtubule-Associated Protein Tau: A Promising Therapeutic Target for Alzheimer Disease
Current Medicinal Chemistry Transgenic Mice as a Model of Pre-Clinical Alzheimers Disease
Current Alzheimer Research Dehydroepiandrosterone (DHEA) and its Sulphate (DHEAS) in Alzheimer’s Disease
Current Alzheimer Research Glycosaminoglycans, Protein Aggregation and Neurodegeneration
Current Protein & Peptide Science Current Understanding of Central Nervous System Drainage Systems: Implications in the Context of Neurodegenerative Diseases
Current Neuropharmacology ADF/Cofilin-Actin Rods in Neurodegenerative Diseases
Current Alzheimer Research Dietary Omega 3 Polyunsaturated Fatty Acids and Alzheimers Disease: Interaction with Apolipoprotein E Genotype
Current Alzheimer Research The State of the Problem of Achieving Extremely Low LDL Levels
Current Pharmaceutical Design Editorial [Hot topic: Parkinsons Disease (Guest Editor: Jurgen Dinges)]
Current Topics in Medicinal Chemistry microRNAs-based Predictor Factor in Patients with Migraine-ischemic Stroke
MicroRNA Neurocognition in the Psychosis Risk Syndrome: A Quantitative and Qualitative Review
Current Pharmaceutical Design Relations between Sensorimotor Integration and Speech Disorders in Parkinson's Disease
Current Alzheimer Research Nanotechnologies: A Strategy to Overcome Blood-Brain Barrier
Current Drug Metabolism Type 2 Diabetes Mellitus and Invokana: An FDA Approved Drug
Current Diabetes Reviews Nutrition as a Health Determinant in Elderly Patients
Current Medicinal Chemistry An Increasing Role of Polyphenols as Novel Therapeutics for Alzheimer’s: A Review
Medicinal Chemistry Oxidative Stress Biology and Cell Injury During Type 1 and Type 2 Diabetes Mellitus
Current Neurovascular Research